PE20180038A1 - Composiciones farmaceuticas topicas - Google Patents

Composiciones farmaceuticas topicas

Info

Publication number
PE20180038A1
PE20180038A1 PE2017002328A PE2017002328A PE20180038A1 PE 20180038 A1 PE20180038 A1 PE 20180038A1 PE 2017002328 A PE2017002328 A PE 2017002328A PE 2017002328 A PE2017002328 A PE 2017002328A PE 20180038 A1 PE20180038 A1 PE 20180038A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
oil
phase
emulsion
topic
Prior art date
Application number
PE2017002328A
Other languages
English (en)
Inventor
Mary BEDARD
Michael Quinn DOHERTY
Jon D Lenn
Leandro L Santos
Sujatha D Sonti
Joey Roger THOMAS
Justin E Whiteman
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081527&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20180038(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20180038A1 publication Critical patent/PE20180038A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion se refiere a composiciones farmaceuticas topicas en emulsion, que comprenden de 0,05% a 2% en peso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno o una de sus sales farmaceuticamente aceptables, una fase oleosa, una fase acuosa, un tensioactivo y un antioxidante, ademas, opcionalmente, puede comprender un conservante, un agente para ajuste de pH, un agente quelante o un co-disolvente, donde dicha composicion en emulsion es homogenea y es una crema tipo aceite en agua. Asimismo, el ingrediente activo se solubiliza en la fase oleosa
PE2017002328A 2015-05-21 2016-05-19 Composiciones farmaceuticas topicas PE20180038A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165097P 2015-05-21 2015-05-21
US201662324450P 2016-04-19 2016-04-19

Publications (1)

Publication Number Publication Date
PE20180038A1 true PE20180038A1 (es) 2018-01-09

Family

ID=56081527

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002328A PE20180038A1 (es) 2015-05-21 2016-05-19 Composiciones farmaceuticas topicas

Country Status (34)

Country Link
US (5) US10195160B2 (es)
EP (2) EP4094752A1 (es)
JP (3) JP6863904B2 (es)
KR (2) KR20240090730A (es)
CN (2) CN107666902B (es)
AU (2) AU2016263161B2 (es)
BR (1) BR112017024934A8 (es)
CA (1) CA2986251A1 (es)
CL (1) CL2017002939A1 (es)
CO (1) CO2017011795A2 (es)
CR (1) CR20170528A (es)
DK (1) DK3297605T3 (es)
DO (1) DOP2017000270A (es)
EA (1) EA038624B1 (es)
ES (1) ES2914112T3 (es)
HK (1) HK1245074A1 (es)
HR (1) HRP20220670T1 (es)
HU (1) HUE059066T2 (es)
IL (2) IL255203B (es)
JO (1) JO3680B1 (es)
LT (1) LT3297605T (es)
MX (2) MX2017014804A (es)
PE (1) PE20180038A1 (es)
PH (1) PH12017502092A1 (es)
PL (1) PL3297605T3 (es)
PT (1) PT3297605T (es)
RS (1) RS63402B1 (es)
SG (1) SG11201708666RA (es)
SI (1) SI3297605T1 (es)
TW (1) TWI705831B (es)
UA (1) UA125500C2 (es)
UY (1) UY36682A (es)
WO (1) WO2016185428A1 (es)
ZA (1) ZA202007965B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11617724B2 (en) * 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
AU2016263161B2 (en) 2015-05-21 2019-02-28 Dermavant Sciences GmbH Topical pharmaceutical compositions
MX2020004785A (es) * 2017-11-10 2020-08-13 Dermavant Sciences GmbH Proceso para preparar tapinarof.
CN109085257B (zh) * 2018-07-05 2021-04-06 中央民族大学 一种同时定量检测小鼠血浆中黄芪甲苷-iv、环黄芪醇的方法
US11497718B2 (en) 2018-11-13 2022-11-15 Dermavant Sciences GmbH Use of tapinarof for the treatment of atopic dermatitis
CA3132958A1 (en) 2019-04-17 2020-10-22 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
US20200383887A1 (en) * 2019-06-04 2020-12-10 L'oreal Oxygenate skin treatment system
CA3144947A1 (en) * 2019-06-26 2020-12-30 Locus Oil Ip Company, Llc Multi-functional compositions comprising concentrated acids for enhanced oil and gas recovery
JP2022541605A (ja) * 2019-07-24 2022-09-26 ソル － ゲル テクノロジーズ リミテッド 局所タピナロフ－ｅｇｆｒ阻害剤組成物による皮膚障害の治療
US20220387349A1 (en) * 2019-09-26 2022-12-08 Sol-Gel Technologies Ltd Treatment of cutaneous adverse effects caused by oncological therapy with topical tapinarof compositions
WO2021059281A1 (en) * 2019-09-26 2021-04-01 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical combination compositions comprising tapinarof and an additional ahr activator
EP4054526A4 (en) * 2019-11-06 2023-05-24 Sol-Gel Technologies Ltd. METHOD OF TREATMENT OF PALMÖBOT TEER KERATODERMA
WO2021100051A1 (en) * 2019-11-24 2021-05-27 Sol-Gel Technologies Ltd. Treatment of skin disorders with topical compositions comprising tapinarof and a pde4 inhibitor
US11154486B2 (en) 2020-02-14 2021-10-26 William M. Yarbrough Foundation Detergent compositions for washing urushiol and methods of treating urushiol induced contact dermatitis
US11191708B2 (en) * 2020-02-17 2021-12-07 William M. Yarbrough Foundation Sodium lauroyl sarcosinate containing detergent compositions
AU2021296867A1 (en) * 2020-06-24 2023-01-19 Dermavant Sciences GmbH Topical pharmaceutical compositions
AU2022223701A1 (en) * 2021-02-17 2023-09-07 Dermavant Sciences GmbH Remittive effects of tapinarof in the treatment of plaque psoriasis, atopic dermatitis, or radiation dermatitis
CA3209718A1 (en) * 2021-02-25 2022-09-01 Gary Michael PEKOE Composition for treatment of topical dermatological bacterial skin conditions
CN113797159A (zh) * 2021-10-22 2021-12-17 冠昊生物科技股份有限公司 一种本维莫德乳膏剂及其制备方法和用途
WO2024050431A2 (en) * 2022-08-30 2024-03-07 Dermavant Sciences GmbH Tapinarof and analogs thereof for use in treating ahr mediated diseases
WO2024124206A1 (en) * 2022-12-08 2024-06-13 Hairdao Payments Llc Topical compositions for treating and preventing hair loss and hair graying

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5111748A (en) 1974-07-16 1976-01-30 Taisho Pharmaceutical Co Ltd Suchirubenjudotaino seizoho
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
JPS58159410A (ja) 1982-03-18 1983-09-21 Mitsubishi Chem Ind Ltd 抗炎症剤
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5008100A (en) 1989-08-11 1991-04-16 Elizabeth Arden Co., Division Of Conopco, Inc. Oil-in-water emulsions containing polyethylene
US6113921A (en) 1993-03-23 2000-09-05 Pharmos Corp. Topical and transdermal delivery system utilizing submicron oil spheres
AU7513994A (en) 1993-07-27 1995-02-28 Agro-Biotech Corporation Novel fungicidal properties of metabolites, culture broth, stilbene derivatives and indole derivatives produced by the bacteria (xenorhabdus) and (photorhabdus) spp.
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JPH1072330A (ja) 1996-09-03 1998-03-17 Kansai Kouso Kk チロシナーゼ活性阻害剤及び化粧料
JPH1143436A (ja) * 1997-07-25 1999-02-16 Showa Denko Kk 末梢血流障害予防・治療剤
EP1987809A1 (en) 1998-02-10 2008-11-05 Shiseido Co., Ltd. Oil-in-water type emulsion composition enthaltend Retinoide
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
FR2777183B1 (fr) 1998-04-10 2001-03-02 Oreal Utilisation d'au moins un hydroxystilbene dans une composition destinee a favoriser la desquamation de la peau et composition le comprenant
AU4084599A (en) 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DE19842730A1 (de) * 1998-09-18 2000-03-23 Beiersdorf Ag Emulgatorfreie feindisperse Systeme vom Typ Öl-in-Wasser und Wasser-in-Öl
FR2785284B1 (fr) 1998-11-02 2000-12-01 Galderma Res & Dev Analogues de la vitamine d
US6761903B2 (en) * 1999-06-30 2004-07-13 Lipocine, Inc. Clear oil-containing pharmaceutical compositions containing a therapeutic agent
US20020054895A1 (en) * 1999-07-23 2002-05-09 Alwyn Company, Inc. Allantoin-containing skin cream
US7321050B2 (en) * 1999-12-06 2008-01-22 Welichem Biotech Inc. Anti-inflammatory and psoriasis treatment and protein kinase inhibition by hydroxy stilbenes and novel stilbene derivatives and analogues
CN1319959C (zh) * 1999-12-06 2007-06-06 天济药业（深圳）有限公司 抗发炎、治疗牛皮癣和抑制蛋白质致活酶的羟基芪、芪衍生物及其类似物
FR2811564B1 (fr) 2000-07-13 2002-12-27 Oreal Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
KR100836207B1 (ko) 2001-01-18 2008-06-09 웰리켐 바이오 테크 인크. 면역 질환 치료용의 신규한 1,2-디페닐에텐 유도체
EP1435894A4 (en) 2001-07-23 2005-07-06 Galileo Pharmaceuticals Inc CYTOPROTECTIVE COMPOUNDS, METHODS AND PHARMACEUTICAL AND COSMETIC FORMULATIONS
RU2212763C2 (ru) * 2001-08-16 2003-09-20 Общество с ограниченной ответственностью "Подсолнечник Технологии" Система открытой оптической связи
AU2003218121A1 (en) * 2002-03-12 2003-09-29 Playtex Products, Inc. Lotion compositions
US20040202634A1 (en) * 2003-03-19 2004-10-14 L'oreal Composition useful for cosmetic or dermatological use containing a block copolymer
CA2559351A1 (en) 2004-03-18 2005-09-22 Panacea Biotec Ltd. Novel compositions for topical delivery
US20060018861A1 (en) * 2004-07-23 2006-01-26 Minghua Chen Skin care composition
DE602005008635D1 (de) * 2004-10-19 2008-09-11 Boots Co Ltd Kosmetische zusammensetzungen
US20060246098A1 (en) * 2005-03-16 2006-11-02 Srinivasa Rao Stable aqueous-based emulsion formulation comprising urea and salicylic acid and method of using same
KR20070057660A (ko) * 2005-12-01 2007-06-07 롬 앤드 하아스 컴패니 활성물을 안정시키기 위한 수성 폴리머 분산액
FR2898498B1 (fr) * 2006-03-15 2008-11-28 Galderma Sa Nouvelles compositions topiques sous forme d'emulsion h/e comprenant un glycol pro-penetrant
US20080206155A1 (en) * 2006-11-14 2008-08-28 Foamix Ltd. Stable non-alcoholic foamable pharmaceutical emulsion compositions with an unctuous emollient and their uses
EP1930499A1 (en) * 2006-12-08 2008-06-11 Cognis IP Management GmbH Tissue paper comprising a softening lotion
EP1938801A1 (en) * 2006-12-22 2008-07-02 Biofrontera Bioscience GmbH Nanoemulsion
WO2009108762A2 (en) 2008-02-26 2009-09-03 The Penn State Research Foundation Methods and compositions for treatment of retinoid-responsive conditions
CA2722445A1 (en) * 2008-04-25 2009-10-29 Nanobio Corporation Nanoemulsions for treating fungal, yeast and mold infections
JP2009291133A (ja) * 2008-06-05 2009-12-17 Snow Brand Milk Prod Co Ltd チーズ食品
WO2010096868A1 (en) * 2009-02-25 2010-09-02 Stiefel Research Australia Pty Ltd Topical foam composition
CN102686205A (zh) * 2009-10-02 2012-09-19 弗艾米克斯有限公司 局部四环素组合物
CN101822638A (zh) * 2009-12-01 2010-09-08 河北科技大学 二苯乙烯类化合物的纳米乳及其制备方法
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
WO2011107478A1 (en) * 2010-03-01 2011-09-09 Photocure Asa Cosmetic compositions
WO2012053007A1 (en) * 2010-10-21 2012-04-26 Cadila Healthcare Limited Topical pharmaceutical compositions containing nanodroplets for the treatment psoriasis
US8883838B2 (en) 2010-12-03 2014-11-11 Allergan, Inc. Pharmaceutical cream compositions and methods of use
CN103930565B (zh) 2011-06-27 2017-06-30 高德美研究及发展公司 用于痤疮的新th17分化标志物及其用途
US20130224268A1 (en) 2012-02-27 2013-08-29 Newgen Biopharma Corp. Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same
CN102657610A (zh) 2012-05-11 2012-09-12 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯微乳剂及其制备方法
CN102657602B (zh) 2012-05-22 2013-08-07 河北科技大学 3,5-二羟基-4-异丙基二苯乙烯壳聚糖凝胶剂及其制备方法
US9433680B2 (en) * 2013-01-31 2016-09-06 Merz Pharmaceuticals, Llc Topical compositions and methods for making and using same
CN103315958B (zh) * 2013-07-19 2014-10-29 河北科技大学 苯烯莫德纳米乳及其制备方法
WO2015085143A2 (en) 2013-12-06 2015-06-11 Stc.Unm Therapeutic agents for skin diseases and conditions
CN103992212B (zh) * 2014-05-29 2015-07-01 河北科技大学 顺式苯烯莫德的合成方法及顺式苯烯莫德的应用
ES2829637T3 (es) 2014-12-12 2021-06-01 Dermavant Sciences GmbH 3,5-dihidroxi-4-isopropil-trans-estilbeno para su uso en el tratamiento tópico del acné
AU2016263161B2 (en) 2015-05-21 2019-02-28 Dermavant Sciences GmbH Topical pharmaceutical compositions
US11617724B2 (en) 2015-05-21 2023-04-04 Dermavant Sciences GmbH Topical pharmaceutical compositions
MX2020004785A (es) 2017-11-10 2020-08-13 Dermavant Sciences GmbH Proceso para preparar tapinarof.

Also Published As

Publication number Publication date
HK1245074A1 (zh) 2018-08-24
SG11201708666RA (en) 2017-12-28
US11458108B2 (en) 2022-10-04
EA201792559A1 (ru) 2018-04-30
US20160338973A1 (en) 2016-11-24
MX2017014804A (es) 2018-02-15
ZA202007965B (en) 2022-12-21
AU2019203627A1 (en) 2019-06-13
KR102669247B1 (ko) 2024-05-27
CA2986251A1 (en) 2016-11-24
WO2016185428A1 (en) 2016-11-24
IL282304A (en) 2021-05-31
EP4094752A1 (en) 2022-11-30
CO2017011795A2 (es) 2018-02-28
CN107666902A (zh) 2018-02-06
EP3297605B1 (en) 2022-05-04
KR20180008490A (ko) 2018-01-24
TWI705831B (zh) 2020-10-01
US10426743B2 (en) 2019-10-01
AU2016263161B2 (en) 2019-02-28
CN107666902B (zh) 2021-09-21
SI3297605T1 (sl) 2022-08-31
AU2019203627B2 (en) 2020-12-24
MX2020012595A (es) 2021-02-09
US20200101027A1 (en) 2020-04-02
CN114042041B (zh) 2023-08-22
HUE059066T2 (hu) 2022-10-28
US20190192445A1 (en) 2019-06-27
US20190192446A1 (en) 2019-06-27
EP3297605A1 (en) 2018-03-28
RS63402B1 (sr) 2022-08-31
IL255203B (en) 2021-05-31
UA125500C2 (uk) 2022-04-13
JP6863904B2 (ja) 2021-04-21
BR112017024934A8 (pt) 2021-03-30
US11622945B2 (en) 2023-04-11
HRP20220670T1 (hr) 2022-08-19
EA038624B1 (ru) 2021-09-24
US20190151255A1 (en) 2019-05-23
JP2023113829A (ja) 2023-08-16
PT3297605T (pt) 2022-05-30
TW201705940A (zh) 2017-02-16
CR20170528A (es) 2018-01-22
LT3297605T (lt) 2022-06-27
BR112017024934A2 (pt) 2018-07-31
PL3297605T3 (pl) 2022-07-11
ES2914112T3 (es) 2022-06-07
US10195160B2 (en) 2019-02-05
IL255203A0 (en) 2017-12-31
US11612573B2 (en) 2023-03-28
CN114042041A (zh) 2022-02-15
AU2016263161A1 (en) 2017-11-16
CL2017002939A1 (es) 2018-03-16
UY36682A (es) 2016-12-30
PH12017502092A1 (en) 2018-05-07
DOP2017000270A (es) 2017-12-15
JO3680B1 (ar) 2020-08-27
DK3297605T3 (da) 2022-06-07
KR20240090730A (ko) 2024-06-21
JP2018515561A (ja) 2018-06-14
JP7531658B2 (ja) 2024-08-09
JP2021105027A (ja) 2021-07-26

Similar Documents

Publication Publication Date Title
PE20180038A1 (es) Composiciones farmaceuticas topicas
BR122021018243A8 (pt) Composição tópica de baixo ph e método para aumentar a aplicação tópica de um ingrediente ativo cosmeticamente aceitável
BR112017021002A2 (pt) composição antimicrobiana, uso de uma composição, método para reduzir substancialmente ou controlar a formação de colônias microbianas sobre ou em uma superfície, sanitizantes para as mãos, produto para o cuidado de ferimentos, e, lenço antimicrobiano
BR112015022972A2 (pt) composição farmacêutica de cloridrato de s-cetamina
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
NZ745859A (en) Antiparasitic isoxazoline compounds, long-acting injectable formulations comprising them, methods and uses thereof
AR081542A1 (es) Composiciones de emulsiones farmaceuticas con bajo contenido de aceite que comprenden un progestageno
CL2020000747A1 (es) Formulaciones de niraparib.
AR105228A1 (es) Formulaciones de emulsiones estables de compuestos volátiles encapsulados
EP4306168A3 (en) Isoxazoline compositions and use thereof in the prevention or treatment of parasite infestations in animals
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
CL2020002252A1 (es) Formulación oftálmica.
BR112017004798A2 (pt) composição farmacêutica que contém um derivado de ácido hidroxâmico ou um seu sal
AR108368A1 (es) Preparación y dispersión de formulaciones de emulsión estable
AR101581A1 (es) Composición de colutorio
BR112019005318A2 (pt) compostos de aza-indazol para uso em lesões no tendão e/ou ligamento
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
HRP20201508T1 (hr) Spojevi s antioksidativnim djelovanjem protiv slobodnih radikala i protupapalnom aktivnosti te odgovarajući farmaceutski pripravci za njegu kože
EA201892563A1 (ru) Композиция для местного применения
AR110648A1 (es) Composiciones veterinarias y los usos de las mismas para prevenir y/o tratar infecciones parasitarias en mamíferos no humanos y kit
UY37867A (es) Formulación de uso tópico para el control y la prevención de parásitos en animales
BR112012024346A2 (pt) agente terapêutico ou agente profilático para a doença de alzheimer
AR103381A1 (es) Composición farmacéutica para el tratamiento de micosis
AR104699A1 (es) Composición farmacéutica tópica en emulsión y su uso para fabricar un medicamento